Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Guy Jerusalem, Gabriella Mariani, Eva Ciruelos, Miguel Martin, Vivianne C G Tjan-Heijnen, Patrick Neven, Joaquín Gavilá, A. Michelotti, Filippo Montemurro, Daniele Generali, E. Simoncini, István Láng, J. Mardiak, Bjørn Naume, M. Camozzi, Katia Lorizzo, S. Bianchetti, Pierfranco Conte

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)'. Together they form a unique fingerprint.

Medicine & Life Sciences